Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist

BACKGROUND. Deficiency of IL-1 receptor antagonist (DIRA) is a rare autoinflammatory disease that presents with life-threatening systemic inflammation, aseptic multifocal osteomyelitis, and pustulosis responsive to IL-1–blocking treatment. This study was performed (a) to investigate rilonacept, a lo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCI Insight
Hlavní autoři: Garg, Megha, de Jesus, Adriana A., Chapelle, Dawn, Dancey, Paul, Herzog, Ronit, Rivas-Chacon, Rafael, Muskardin, Theresa L. Wampler, Reed, Ann, Reynolds, James C., Goldbach-Mansky, Raphaela, Sanchez, Gina A. Montealegre
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2017
Témata:
Clinical Medicine
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5621891/
https://ncbi.nlm.nih.gov/pubmed/28814674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.94838
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky